Article
TECHNOLOGYREVIEW
(2022)
A covid pill could cut serious illnesses and help prevent the next pandemic. But it's expensive and in short supply.
FoundryBase
updated about 6 hours ago
Comments
Related Chunks
Related chunks with this resource
Pfizer - developing a treatment, cure candidate for COVID19 Coronavirus
RELATED RESOURCES
with chunks in common
2021
Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19
Saved by: FoundryBase
used in 2 chunks
2021
Pfizer antiviral pill reduced risk of covid hospitalization and death by 89 percent in high-risk people
Saved by: FoundryBase
used in 1 chunk
MORE RELATED CONTENT
with shared categories
2022
12 Things To Know About Paxlovid, the Latest COVID-19 Pill > Yale Medicine
Saved by: FoundryBase
used in 1 chunk
2021
FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline
Saved by: FoundryBase
used in 1 chunk
2021
Pharmaceuticals and innovation. Less buck for the bang. Are drug patents worth it?
Saved by: FoundryBase
used in 2 chunks
2021
South African Covid variant may cut antibody protection from Pfizer vaccine by two-thirds
Saved by: FoundryBase
used in 2 chunks
2021
What went wrong with America’s $44 million vaccine data system? | MIT Technology Review
Saved by: FoundryBase
used in 4 chunks
2021
Covid-19: Novavax vaccine shows 89% efficacy in UK trials - BBC News
Saved by: FoundryBase
used in 1 chunk
2021
Sanofi to help produce 100 million Pfizer/BioNTech vaccine doses | Reuters
Saved by: FoundryBase
used in 3 chunks
2021
In a major setback, Merck to stop developing its two Covid-19 vaccines and focus on therapies
Saved by: FoundryBase
used in 2 chunks
2021
Personalized Skin Cancer Vaccine Shows Promise in New Trial Results
Saved by: FoundryBase
used in 4 chunks
2020
Sanofi suffers major setback in development of a Covid-19 vaccine
Saved by: FoundryBase
used in 1 chunk
2020
Why Did the U.S. Turn Down Pfizer Vaccine Doses? - The New York Times | Podcast
Saved by: FoundryBase
used in 1 chunk
No comments yet. Be the first to comment!